ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1991

Large Vessel Involvement By IgG4-Related Disease

Cory Perugino1, Zachary Wallace1 and John H. Stone2, 1Rheumatology, Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: IgG4 Related Disease, large vessel vasculitis, rituximab and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Vasculitis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition of uncertain etiology. Reports have described inflammatory aortitis and peri-aortitis in the setting of retroperitoneal fibrosis (RPF) but have not adequately distinguished between these two manifestations. The frequency, radiologic features, and response of vascular complications to B cell depletion remain poorly-defined.  We describe the clinical features, radiology findings, and treatment response in a large cohort of patients with IgG4-RD affecting the large vessels.

Methods:

All patients had biopsy-proven IgG4-RD. Clinical records of all patients diagnosed with IgG4-RD in our Center were reviewed. All radiologic studies were reviewed independently by two vascular radiologists.  We distinguished between primary large blood-vessel inflammation and secondary vascular involvement, defined as disease related to the effects of adjacent inflammation (e.g., peri-aortitis associated with retroperitoneal fibrosis).

Results:

Of the 160 IgG4-RD patients in this cohort, 36 (22.5%) had large-vessel involvement. The mean age of the patients with large-vessel manifestations of IgG4-RD was 54.6 years. Twenty-seven (75%) were male and nine (25%) were female.  Fifteen patients (42%) had primary involvement of their vasculature by IgG4-RD (IgG4-related vasculitis). Inflammatory aortic aneurysms (IAA), which affected eleven patients – 7% of the cohort overall – were observed in the abdominal aorta in seven cases, the thoracic aorta in seven, and both the thoracic and abdominal aorta in three.  IAA of either the thoracic or abdominal aorta or both comprised the most common manifestation of IgG4-related vasculitis.  Three patients had aortic dissection or contained perforation. Peri-aortitis in the setting of RPF accounted for 25 of 27 cases (93%) of secondary vascular involvement by IgG4-RD.  Six patients demonstrated evidence of both primary and secondary blood vessel involvement. Twenty-two of the 36 patients with vascular disease were treated with rituximab and 62.5% showed stabilized or improved radiologic findings following treatment.

Conclusion:

IgG4-RD is a unique, distinctive and treatable cause of large-vessel vasculopathy, comprising both primary vasculitis and secondary vascular involvement. The most common manifestation of IgG4-related vasculitis is inflammatory aortic aneurysm. Peri-aortitis with sparing of the aortic wall is the most common secondary vascular manifestation.


Disclosure: C. Perugino, None; Z. Wallace, None; J. H. Stone, Roche, Genentech, 2,Genentech, 5.

To cite this abstract in AMA style:

Perugino C, Wallace Z, Stone JH. Large Vessel Involvement By IgG4-Related Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/large-vessel-involvement-by-igg4-related-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/large-vessel-involvement-by-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology